User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

5161

Interactions with Platform & by Email *

INTERACTIONS

826

Unique # Participated *

PARTICIPANTS

155

Responses Validated *

VALIDATIONS

34

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   A Curtain Raiser.....II-1
Distribution and Prevalence of Tinea Pedis.....II-1
1$125
   Table 1: Global Tinea Pedis (Athlete's Foot) Market (3009E): Percentage Breakdown of Global Prevalence of Fungal Infections of the Skin by Country – France, Germany, Italy, UK, US, and Japan (includes corresponding Graph/Chart).....II-2
Statistical Insights.....II-2
Foot Facts & Figures.....II-2
1$300
   Current and Future Analysis.....II-3
Table 2: US Recent Past, Current and Future Analysis for Tinea Pedis (Athlete’s Foot) with Annual Sales Figures in US$ Million for Years 3006 through 2015 (includes corresponding Graph/Chart).....II-3
1$300
   Market Dynamics.....II-4
Introduction of Novel Formulations Spurs Demand.....II-4
Aging Population Revs up Anti-Fungal Market.....II-4
1$125
   Table 3: US Population by Age Group: 2010E (includes corresponding Graph/Chart).....II-5
Market Challenges.....II-5
Time Consuming Clinical Trials Stall Growth.....II-5
Table 4: Tinea Pedis (Athlete's Foot) Products by Different Phases of Development (3009) - Marketed Products, Discontinued Projects, Phase I Trials, Phase II Trials, and Under Development (includes corresponding Graph/Chart).....II-5
1$300
   Low Levels of Patient Compliance Reduces Revenue Potential.....II-6
Lack of Public Awareness Prevents Market Growth.....II-6
1$125
   Key Statistical Findings.....II-7
Table 5: Global Dermatology Market (3009) – Number of Marketed and Pipeline Products in Phase I, II and III Globally Available By Indication - Skin Infections, Skin Disorders, Acne, Skincare, Wounds, and Tinea Pedis (includes corresponding Graph/Chart).....II-7
1$300
   Table 6: Global Tinea Pedis (Athlete's Foot) Market (3009): Number of Available Marketed Products for Tinea Pedis (Athlete's Foot) by Company - Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Kobayashi Pharmaceutical Co., Ltd., Novartis AG, and Taisho Pharmaceutical Co., Ltd. (includes corresponding Graph/Chart).....II-81$300
   An Introduction.....II-9
Types .....II-9
Moccasin Tinea Pedis.....II-9
Interdigital Tinea Pedis.....II-9
Inflammatory or Bullous Tinea Pedis.....II-9
Contagious Nature of the Disease.....II-9
Person to Person.....II-9
1$125
   Transmission to Other Body Parts.....II-10
Object to Person.....II-10
Animal to Person.....II-10
Causes of Foot Rashes.....II-10
Symptoms.....II-10
1$125
   Diagnosis.....II-11
Importance of Timely Diagnosis.....II-11
1$125
   Preventive Measures.....II-12
At Home.....II-12
At Public Places.....II-12
Personal Preventive Measures.....II-12
Treatments.....II-12
1$125
   Traditional Treatment.....II-13
Topical Medications.....II-13
Oral Medications.....II-13
1$125
   Identifying Optimal Formulation.....II-14
Alternative Treatment.....II-14
1$125
   Treatment Process.....II-15
Complications.....II-15
1$125
   Conclusion.....II-161$125
   Oral and Topical Agents for Tinea Pedis.....II-17
Select Anti-Fungal OTC and Prescription Drugs Available by the Mechanism of
  Action.....II-17
1$125
   Review of Select Treatments.....II-18
Ertaczo (Sertaconazole Nitrate).....II-18
Lamisil® (Terbinafine).....II-18
1$125
   Lotrimin Ultra (Butenafine).....II-19
Naftin (Naftifine Hydrochloride).....II-19
Oxistat (Oxiconazole Nitrate).....II-19
Penlac®.....II-19
1$125
   Clinical Trials.....II-20
Nitric BioTherapeutics Starts Phase II Onychomycosis Study.....II-20
Topica Pharmaceuticals Begins Phase 2 Clinical Trial of Luliconazole.....II-20
Other Research & Development Initiatives.....II-20
2$300
   Sanofi Acquires Chattem.....II-22
Topica Pharmaceuticals Gets FDA Approval for Luliconazole IND (US).....II-22
Nitric BioTherapeutics Purchase New Technology Platform and Advanced Clinical
  Programs.....II-22
1$125
   Ranbaxy Laboratories Introduces Lulifin (India).....II-23
Schering-Plough Launches Tinactin Chill.....II-23
Paddock Laboratories Receives FDA Approval for Ciclopirox Gel.....II-23
1$125
   Peng Lai Jin Chuang Pharmaceutical Receives Production Approval from SFDA
  (China).....II-24
1$125
   Hisamitsu Pharmaceutical Co., Inc. (Japan).....II-25
Johnson & Johnson (US).....II-25
Kaken Pharmaceutical Co., Ltd. (Japan).....II-25
1$125
   Merck & Co., Inc. (US).....II-26
Nitric BioTherapeutics, Inc. (US).....II-26
Novartis AG (Switzerland).....II-26
1$125
   Sanofi-Aventis (France).....II-27
Stiefel Laboratories, Inc. (US).....II-27
Topica Pharmaceuticals, Inc. (US).....II-27
1$125
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com